Tertomotide - KAEL-GemVax

Drug Profile

Tertomotide - KAEL-GemVax

Alternative Names: GV1001; hTERT RNA vaccine - KAEL-GemVax; LucaVax; Telomerase peptide vaccine - KAEL-GemVax; TeloVac

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmexa
  • Developer Affitech A/S; Cancer Research UK; KAEL-GemVax; Lytix Biopharma; Norwegian Radium Hospital; Pharmexa
  • Class Cancer vaccines; Peptide fragments; Ribonucleoproteins
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic cancer
  • Phase II Alzheimer's disease; Benign prostatic hyperplasia; Non-small cell lung cancer
  • Phase I/II Malignant melanoma
  • No development reported Solid tumours
  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 21 Mar 2018 KAEL-GemVax plans a phase III trial for Benign prostatic hyperplasia
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Adjuvant therapy) in Norway (Intradermal, Injection)
  • 01 Jun 2017 Phase-II clinical trials in Alzheimer's disease (Treatment-experienced) in South Korea (SC) (NCT03184467)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top